BTAI

Pre-mercato: 1.05 -0.01 -0.94%

Bioxcel Therapeutics Inc (BTAI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BTAI Giù? Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Bioxcel Therapeutics Inc

Healthcare (1110)

203-643-8060

555 LONG WHARF DRIVE, NEW HAVEN, CT

Prossima data di guadagno

Ultimi documenti SEC

BTAI's Discussions on Twitter

Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BTAI Bioxcel Therapeutics Inc	1.06	28.70M	642.00K	-69.90M	-57.62M	-7.152
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-17	Iniziato	Rodman & Renshaw	Buy
2024-02-21	Downgrade	UBS	Buy → Neutral
2023-08-15	Downgrade	Mizuho	Buy → Neutral
2023-07-17	Downgrade	Guggenheim	Buy → Neutral
2023-03-10	Downgrade	Jefferies	Buy → Hold
2022-12-01	Aggiornamento	Goldman	Sell → Neutral
2022-07-07	Iniziato	Mizuho	Buy
2022-04-06	Reiterato	BofA Securities	Buy
2021-11-15	Downgrade	Goldman	Neutral → Sell
2021-04-09	Iniziato	Berenberg	Buy
2021-02-01	Iniziato	UBS	Buy
2020-10-30	Iniziato	Goldman	Buy
2020-09-02	Iniziato	Jefferies	Buy
2020-08-17	Reiterato	H.C. Wainwright	Buy
2020-07-08	Reiterato	H.C. Wainwright	Buy
2020-06-04	Iniziato	Guggenheim	Buy
2020-04-01	Iniziato	BofA/Merrill	Buy
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-01-08	Reiterato	H.C. Wainwright	Buy
2019-11-12	Iniziato	SunTrust	Buy

Mostra tutto

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Yahoo Finance

H.C. Wainwright reiterates BioXcel Therapeutics stock rating at buy By Investing.com - Investing.com Canada

H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz

BioXcel Therapeutics, Inc. Share Price TodayLive NASDAQ: BTAI Stock Price Charts, History - Upstox

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - Sahm

BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - Yahoo! Finance Canada

BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Australia

Jobs Data: Is BioXcel Therapeutics Inc a strong candidate for buy and hold2026 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn

BioXcel Therapeutics announces enrollment of first patients in U.S. Department of War-funded study of BXCL501 (sublingual dexmedetomidine) for treatment of acute stress reactions - marketscreener.com

BioXcel begins DoW-funded trial of BXCL501 for acute stress By Investing.com - Investing.com Canada

BioXcel drug enters U.S. military-funded study for acute stress after trauma - Stock Titan

BTAI Forecast, Price Target & Analyst Ratings | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill

BTAI Technical Analysis & Stock Price Forecast - Intellectia AI

BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore

BTAI Should I Buy - Intellectia AI

BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus

H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com South Africa

H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com

H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo

FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa

FDA accepts BioXcel filing for at-home use of agitation drug By Investing.com - Investing.com South Africa

FDA accepts BioXcel filing for at-home use of agitation drug - Investing.com Australia

BTAI: FDA Reviews BioXcel's Home Use Application for Igalmi - GuruFocus

FDA Accepts BioXcel sNDA for At-Home IGALMI Use - TipRanks

BioXcel Therapeutics Announces Food and Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - marketscreener.com

FDA accepts BioXcel Therapeutics application for IGALMI in at-home agitation treatment - Investing.com UK

FDA accepts BioXcel filing for at-home agitation treatment - Investing.com

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - The Manila Times

BioXcel Therapeutics (BTAI) gets FDA review date for IGALMI at-home agitation use - Stock Titan

BTAI.O Forecast — Price Prediction for 2026. Should I Buy BTAI.O? - Intellectia AI

BTAI.O PE Ratio & Valuation, Is BTAI.O Overvalued - Intellectia AI

BTAI.O Technical Analysis & Stock Price Forecast - Intellectia AI

Certain Common Stock of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com

Certain Warrants of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com

BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - Bitget

Why are BioXcel Therapeutics shares down Friday? - MSN

Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI) - The Globe and Mail

Qatar Investment Authority (BTAI) reports 156,066 BioXcel shares owned - Stock Titan

Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World

Free cash flow per share of BioXcel Therapeutics, Inc. – FWB:BX20 - TradingView

How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks - Yahoo Finance

SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a BTAI